Advertisement

Expert Point of View: Eleni Efstathiou, MD


Advertisement
Get Permission

Eleni Efstathiou, MD

Eleni Efstathiou, MD

Formal study discussant Eleni Efstathiou, MD, of MD Anderson Cancer Center, Houston, was enthusiastic about the PROfound trial results. “This is the first phase III targeted therapy trial to deliver positive outcomes in metastatic castration-resistant prostate cancer,” she stated. “This is truly a practice-changing study, not just for our patients but for the design of other studies. We can successfully identify candidates for olaparib. We saw a clinically meaningful improvement in outcomes for patients with homologous recombinant repair genetic alterations, driven mainly by BRCA2,” added Dr. Efstathiou.

“We are entering the targeted therapy era for prostate cancer, and we can go to marker-driven research that is specific to DNA damage and repair alteration. We need to treat earlier in the disease and decide which genes to target. We will need community education to secure access [through genomic testing] to these novel strategies. This trial moves the field forward. We strive for progress—not perfection—and this trial represents progress,” Dr. Efstathiou told listeners. 

DISCLOSURE: Dr. Efstathiou reported financial relationships with Bayer HealthCare, Takeda Pharmaceuticals North America, Tolmar, Sanofi, Astellas Pharma, Janssen Pharmaceuticals, and Medivation.


Related Articles

Targeted Therapy Moves Into Metastatic Castration-Resistant Prostate Cancer With Strong Showing by Olaparib and Rucaparib

Treatment with olaparib delayed disease progression, and early survival data suggest a positive trend in favor of olaparib compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair genetic alterations—specifically...

Advertisement

Advertisement



Advertisement